DEF: Amwell's 2026 Annual Meeting: Focus on Strategy and Governance

American Well Corporation announces its 2026 Annual Meeting of Stockholders, highlighting strategic progress, financial performance, and corporate governance matters.

Summary

• The document is a proxy statement for American Well Corporation's (Amwell) 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026.
• Key proposals include the election of directors, ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation.
• The company reports significant progress in 2025, transitioning to a tech-enabled care platform, increasing subscription software revenues, and improving operational efficiency.
• Net loss improved by over 55% in 2025 compared to 2024.
• Amwell highlights the successful deployment of its SaaS platform for the U.S. Defense Health Agency (DHA) Digital First initiatives.
• Total revenue for 2025 was $249.3 million, with subscription revenue at $132.4 million and AMG visit revenue at $94.3 million.
• Gross margin was 53%, and the net loss was $95.0 million in 2025, an improvement from $212.6 million in 2024.
• Total visits reached 4.5 million in 2025.
• Cash and short-term securities stood at approximately $182.3 million at year-end 2025.
• The company is focused on achieving operating cash flow breakeven by the end of 2026.
• Amwell is divesting non-core assets, including the sale of its Amwell Psychiatric Care business, to concentrate on its core platform.
• The company emphasizes the integration of AI in healthcare and its ability to supplement automated programs with certified providers.
• The Board of Directors consists of 9 members, with 22% women, 78% independent, and 33% military veterans.
• Dr. Peter Slavin will not seek re-election, reducing the board size to 8 members.
• Ido Schoenberg and Roy Schoenberg are nominated for re-election as Class III directors.
• The company is a controlled company, with Drs. Ido and Roy Schoenberg holding 51% of the voting power.
• Non-employee directors receive annual cash retainers and RSU grants, with stock ownership guidelines in place.
• A policy for reviewing related person transactions is in place, with the Audit Committee responsible for approval.
• Dan Wahrhaft, son of Dr. Ido Schoenberg, received $229,165 in compensation in 2025.
• Executive compensation is structured with base salary, annual cash incentives, and long-term equity awards, emphasizing pay-for-performance.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, highlighting significant operational improvements and strategic progress, but also acknowledging continued net losses and the exclusion of certain programs from a key contract.

Positives

• Significant improvement in net loss, decreasing by over 55% in 2025 compared to 2024.
• Successful deployment of SaaS platform for the U.S. Defense Health Agency (DHA) Digital First initiatives.
• Total revenue of $249.3 million in 2025, with subscription revenue comprising a significant portion ($132.4 million).
• Achieved a gross margin of 53% in 2025.
• Strong cash position with approximately $182.3 million in cash and short-term securities at year-end 2025.
• High satisfaction reported for virtual visits powered by the DHA platform.
• Focus on strategic priorities and operational efficiency leading to improved financial performance.
• Commitment to achieving operating cash flow breakeven by year-end 2026.
• Divesting non-core assets to focus on core platform offering.
• High support (97%) for the company's executive compensation program in the 2025 advisory vote.
• All non-employee directors were compliant with stock ownership guidelines as of December 31, 2025.
• All current executive officers are in compliance with or on track to meet stock ownership guidelines.

Negatives

• Budget restrictions led to the exclusion of behavioral health and automated care programs from the 2026 DHA contract extension.
• Net loss of $95.0 million in 2025, indicating continued unprofitability.
• The company is still working towards achieving positive cash flow from operations.
• Dr. Peter Slavin will not seek re-election to the Board of Directors.
• Two late Form 4 filings were reported for Dan Zamansky and Deborah Jackson regarding RSU grants.
• No amounts were earned under the Operating Cash Flow Measures for the CEO's 2025 long-term incentive award.
• As of December 31, 2025, no performance milestones were met for certain performance-based market condition share awards for the CEO.

Risks

• Budget restrictions impacting the scope of the DHA contract extension.
• Market fragmentation challenges in the healthcare landscape.
• Increased complexity and cost associated with inefficient data exchange in healthcare.
• Potential for future enterprise-wide adoption of behavioral health and automated care programs with the DHA is not guaranteed.
• The company's ability to achieve operating cash flow breakeven by year-end 2026 is dependent on continued execution of its plan.
• Risks associated with macroeconomic factors, including inflation and rising interest rates, were considered in setting performance targets.
• The company's insider trading policy prohibits hedging and pledging of company securities, which could limit certain investor strategies.
• Potential for future restatements of financial results could lead to recoupment of incentive compensation under the clawback policy.

Future Outlook

Amwell is focused on executing its plan to achieve operating cash flow breakeven by the end of 2026. The strategy involves leveraging its differentiated platform in select market segments and ensuring operational efficiency. The integration of AI across healthcare is seen as a significant catalyst for the evolution of tech-enabled care, with Amwell positioned to enable safe and effective adoption of AI-driven solutions by supplementing automated programs with trusted in-network providers.

Management Comments

• "2025 was a transformative year for Amwell as we executed against our strategic priorities with discipline and focus."
• "Our mission to transform healthcare through technology has never been more relevant, and I am pleased to report significant progress toward our goal of achieving positive cash flow from operations in 2026."
• "Our partnership with the U.S. Defense Health Agency (DHA) represents a cornerstone achievement."
• "While budget restrictions led to the exclusion of our behavioral health and automated care programs from the 2026 contract extension, we remain confident in the clinical efficacy and cost-effectiveness of these solutions and believe they strongly support future enterprise-wide adoption."
• "The integration of AI across healthcare represents the most significant catalyst for the evolution of tech-enabled care."
• "Our long journey is in many ways only beginning, and we are excited about the future we are building for our customers, our company, and you, our valued shareholders."

Industry Context

StockSavvy.ai notes that Amwell's focus on a tech-enabled care platform and subscription revenue aligns with broader industry trends towards integrated digital health solutions. The company's strategy to address market fragmentation by offering a unified platform with white-labeling capabilities positions it to capitalize on the increasing demand for consolidated digital health services among employers and health plans.

Comparison to Industry Standards

• The reported gross margin of 53% is competitive within the health tech and SaaS sectors, though direct comparisons require detailed analysis of specific service offerings and cost structures.
• The improvement in net loss by over 55% demonstrates effective cost reduction and margin expansion efforts, which is a positive indicator compared to many growth-stage companies in the digital health space that often prioritize growth over immediate profitability.
• The company's partnership with the U.S. Defense Health Agency (DHA) for digital health initiatives is a significant achievement, potentially setting a benchmark for large-scale government deployments of telehealth platforms.
• The stated goal of achieving operating cash flow breakeven by year-end 2026 is a critical milestone for sustainable growth, a common objective for companies in this sector aiming to transition from investment-heavy growth phases to profitability.

Management Changes

Corporate Governance

Related Party Transactions

• Dan Wahrhaft, son of Dr. Ido Schoenberg, is employed as Vice President, Sales & Account Management and received $229,165 in compensation in 2025.
• The company provides telehealth services to affiliated parties, including Cleveland Clinic.
• Indemnification agreements are in place with directors and executive officers.

Stakeholder Impact

• Shareholders: The company's focus on achieving profitability and positive cash flow, along with strategic divestitures, aims to create long-term shareholder value. The advisory vote on executive compensation indicates a focus on aligning management incentives with shareholder interests.
• Employees: The company emphasizes talent development, engagement, and wellbeing. Executive compensation includes equity awards to foster an ownership culture.
• Customers: The platform aims to improve patient experience, expand access to care, and enhance operational efficiencies for clients.
• Providers: The platform supports care teams by unifying resources, driving efficient workflows, and reducing administrative burdens, allowing them to focus on patient care.

Next Steps

• Attend the 2026 Annual Meeting of Stockholders on June 16, 2026.
• Vote on the election of directors, ratification of auditors, and advisory approval of executive compensation.
• Monitor progress towards achieving operating cash flow breakeven by year-end 2026.
• Observe the impact of divesting non-core assets and focusing on the core platform.
• Evaluate the integration of AI across healthcare and its impact on Amwell's offerings.

Key Dates

Recommendation

The filing indicates progress towards operational efficiency and a strategic shift towards a tech-enabled platform, with improved net loss figures. However, the company remains unprofitable, and key contract extensions faced budget restrictions. While the outlook for achieving cash flow breakeven by year-end 2026 is positive, the path to sustained profitability and growth requires further execution and market validation. Therefore, a 'hold' recommendation is appropriate pending clearer evidence of consistent financial improvement and successful expansion of key partnerships.

Keywords

American Well Corporation, Amwell, Proxy Statement, DEF 14A, Annual Meeting of Stockholders, Executive Compensation, Corporate Governance, Director Election, PricewaterhouseCoopers LLP, Auditor Ratification, Telehealth, Digital Health, SaaS Platform, Defense Health Agency, Financial Performance, Net Loss, Revenue, Gross Margin, Cash Flow, Stockholder Value